Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.

doi:10.1182/blood.2021011304

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.

Blood - 20 Jan 2022

Estey Elihu, Hasserjian Robert P, Döhner Hartmut

Abstract excerpt

Patients with acute myeloid leukemia (AML) have conventionally received more intense therapy than patients with myelodysplastic syndrome (MDS). Although less intense therapies are being used more often in AML, the dichotomy between AML and MDS remains, with the presence of ≥20% myeloblasts in marrow or peripheral blood generally regarded as defining AML. Consequently, patients with 19% blasts are typically...

Topics

Adult
Aged
Aged, 80 and over
Chromosome Aberrations
Diagnosis, Differential
Female
Gene Rearrangement
Humans
Leukemia, Myeloid, Acute
Male
Middle Aged
Mutation
Myelodysplastic Syndromes
Nucleophosmin
Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 34111285
DOI: 10.1182/blood.2021011304
PMCID: PMC8832464

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics